Skip to main
PRQR

ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics (PRQR) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProQR Therapeutics is in a unique position to address severe genetic rare diseases through its RNA-based therapeutics. With a strong pipeline of promising drugs and a focus on cholestatic diseases, the Company has a strong competitive advantage in this space. Despite facing significant competition and regulatory risks, ProQR's innovative approach to targeting RNA holds great potential for success in the future. The Company's healthy financials, including a strong cash position and strategic partnerships, also bode well for its future prospects.

Bears say

ProQR Therapeutics is a biopharmaceutical company with a single focus on RNA-based therapeutics for rare genetic diseases. While the potential for market exclusivity and orphan drug designations could provide some protection, the company faces significant competition in the gene therapy/RNA medicines space. Additionally, the need for future fundraising and the complexity and uncertainty of valuing a development stage company contribute to the negative outlook on the stock.

ProQR Therapeutics (PRQR) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProQR Therapeutics (PRQR) Forecast

Analysts have given ProQR Therapeutics (PRQR) a Strong Buy based on their latest research and market trends.

According to 3 analysts, ProQR Therapeutics (PRQR) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProQR Therapeutics (PRQR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.